We see the unseen.

At Alexion, we see opportunities where others do not and we have the courage to explore what others believe is impossible. We see patients suffering from devastating diseases that are often overlooked. We see a pathway from innovative science to the delivery of breakthrough therapies.

Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

Welcome to the Alexion Canada website. We opened our doors in Canada in 2009 and currently run our country operations from our office in Vaughan, ON. We are a team of dedicated professionals committed to providing life-transforming treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options.

In Canada, Soliris® (eculizumab) is approved by Health Canada for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (atypical HUS). Both PNH and atypical HUS are ultra-rare diseases that are severe, chronic, progressive and life-threatening, with a profound impact on patients, their families and society.

We are currently conducting clinical trials with Canadian researchers for rare diseases that affect the kidneys, blood, brain and other vital organs where the complement system plays a role and where current treatment options remain inadequate. Our goal is to bring new hope with our products to these underserved patient populations.

At Alexion Canada we are about making a difference in the lives of our patients and their families.

Thank you for visiting the Alexion Pharma Canada website.

— John Haslam, General Manager,
Alexion Pharma Canada Corp.

 

LATEST NEWS

 

Seeing the Unseen for 25 Years

For 25 years, Alexion has seen opportunities where others have not. We have had the courage to explore what others believe is impossible. And we have forged a pathway from innovative science to breakthrough therapies for patients suffering from devastating diseases that had previously been overlooked. Learn more.


Learn More About the PMPRB Hearing with Alexion Canada


Alexion Employees in Canada Join Colleagues Around the World for Global Day of Service

On September 23, 2016, more than 1,500 Alexion employees volunteered in their local communities as part of the Company’s first Global Day of Service. The event helped inspire and connect employees with a common purpose and brought hands-on support to some of the most pressing needs in our local neighbourhoods.


Employees in Canada joined the effort by decorating and painting a children’s playroom for Yellow Brick House, an organization providing emergency shelter and outreach services for women and children who have experienced violence and abuse. Read our press release to learn more.


Health Canada Approves Strensiq™ (asfotase alfa), the First Therapy for Patients with Hypophosphatasia (HPP), an Ultra-Rare, Life-threatening Disease